Friday 26th April 2019
|Text too small?|
Pure Cann New Zealand, which counts former Air New Zealand boss Rob Fyfe as its executive chair, has secured $6 million from Australia's Cann Group for a 20 percent stake in the local medicinal cannabis company.
The investment will be made over stages with the initial 10 percent to be completed on or before Aug. 30 and a further 10 percent when New Zealand regulations come into force and Pure Cann's board approves the construction of its commercial cultivation facility.
The New Zealand government anticipates introducing new regulations, licensing requirements and quality standards governing medicinal cannabis usage by the end of this calendar year.
ASX-listed Cann Group has the option to increase its position to 30 percent.
Fyfe, currently Pure Cann's second largest shareholder with a 25.2 percent stake, said the move is a "pivotal moment for New Zealand's medicinal cannabis industry."
The strategic investment and a technical services agreement - which allows for mutual sharing of intellectual property - "ensure that Pure Cann is now fully funded and, more importantly, allows us to leverage the cultivation, production and technical leadership of Cann Group," the former Icebreaker chair said.
The move lets the two companies work together to "capitalise on the growing demand for medicinal cannabis in New Zealand and explore potential export opportunities as Pure Cann develops its own proposed cultivation and production facilities," said Cann Group chief executive Peter Crock.
Cann Group has established research and cultivation facilities in Melbourne and is looking to provide access to medicinal cannabis for Australian patients. Aurora Cannabis, one of Canada's largest listed medicinal cannabis companies, owns 22.9 percent of the Australian firm.
"Pure Cann is proposing to develop a range of organic medicinal cannabis products to serve patient needs in New Zealand and potential export markets," Crock said. "We are confident that Pure Cann will be able to leverage New Zealand's global reputation for development world leading premium and natural products."
No comments yet
NZ dollar stalled; US-China trade deal may be postponed
AFT Pharmaceuticals starts to hit its straps
Crown seeks US$100m from Tui operator; Prospector moving on
Pacific Edge goes back to shareholders for another $20m
Crown seeks $100m from Tui operator Tamarind
Ryman underlying annual profit may rise by up to 17%
NZ dollar eases on increasing US-China doubts, lack of news in Fed minutes
From dog tucker to top dog: economists ask how Northport can be Auckland’s best replacement
MARKET CLOSE: NZ shares rise; Metlife jumps on takeover talk
NZ dollar eases on technical factors, buoyed by higher dairy prices